Group of Translational Research in Digestive Diseases, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.
Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain.
Front Cell Infect Microbiol. 2021 Jul 20;11:709749. doi: 10.3389/fcimb.2021.709749. eCollection 2021.
Over half of the world's population is estimated to be infected with . Chronic infection with this microbial class I carcinogen is considered the most important risk factor for developing gastric cancer. The increasing antimicrobial resistance to first-line antibiotics mainly causes the failure of current eradication therapies, inducing refractory infections. The alarming increase in multidrug resistance in isolates worldwide is already beginning to limit the efficacy of existing treatments. Consequently, the World Health Organization (WHO) has included in its list of "priority pathogens" for which new antibiotics are urgently needed. Novel strategies must be followed to fight this antibiotic crisis, including properly exploiting the proven therapeutic potential of medicinal plants and plant-derived phytochemicals. In this mini-review, we overview the impressive properties of naturally occurring flavonoids as effective antimicrobial agents against , which support the use of these plant-derived bioactive compounds as promising drug candidates for inclusion in novel and personalized combinatory therapies against infection.
据估计，世界上超过一半的人口感染了幽门螺杆菌。这种微生物类 I 致癌物的慢性感染被认为是导致胃癌的最重要危险因素。目前根除疗法的失败主要是由于对抗生素的耐药性不断增加，导致难治性感染。世界各地幽门螺杆菌分离株的多药耐药性令人震惊地增加，已经开始限制现有治疗方法的疗效。因此，世界卫生组织（WHO）已将其列入“优先病原体”清单，急需开发新的抗生素。必须采取新的策略来应对这场抗生素危机，包括充分利用药用植物和植物源性植物化学物质已被证实的治疗潜力。在这篇迷你综述中，我们概述了天然存在的类黄酮作为有效抗菌剂对抗幽门螺杆菌的令人印象深刻的特性，这支持将这些植物源性生物活性化合物用作有前途的候选药物，纳入针对幽门螺杆菌感染的新型个性化联合疗法。
